Over 10 years experience of Traceability Solutions
By Pharmatrax Author
Category: Technoloy
No Comments
Despite decades of research and therapeutic advances, cancer remains a global scourge and is currently the second leading cause of mortality. According to the American…
By Pharmatrax Author
Category: News
No Comments
Developing new drugs is incredibly hard. That’s why, despite superhuman efforts from the industry, we’re still looking at 12-18 months minimum before we can realistically…
By Pharmatrax Author
Category: Technoloy
No Comments
For a few years, thought leaders across the global economy have invested hopes that blockchain, the record-keeping technology behind Bitcoin, could bring transparency across the…
By Pharmatrax Author
Category: News
No Comments
With the Dow Jones Industrial Average, the Nasdaq Composite Index, and the S&P 500 all down by more than 20% from their recent highs, there’s no doubt that the…
By Pharmatrax Author
Category: Technoloy
No Comments
Large pharmaceuticals are hoarding data needed for a coronavirus cure. There is a precedent to share it, and retain commercial confidentiality. In brief Some of…
By Pharmatrax Author
Category: News
No Comments
Six unique plant molecules have shown the ability to halt the alarming multiplication of the SarsCoV-2 virus in an Artificial Intelligence (AI) modelling used by…
By Pharmatrax Author
Category: Technoloy
No Comments
Tech Nation provides an extensive roundup of UK healthtech companies that are tackling the coronavirus pandemic via innovative solutions How are UK healthtech companies fighting…
By Pharmatrax Author
Category: Technoloy
No Comments
3D printing is revolutionizing the medical field as we know it. The market is expected to rocket up 308% to $44.4 billion in 2025. I’ll…
By Pharmatrax Author
Category: News
No Comments
It’s an all-hands – and robotic arms – on deck period in American history with manufacturers across the country leveraging technology to help combat COVID-19.…
By Pharmatrax Author
Category: News
No Comments
Circumventing patents to combat Covid-19 is understandable but does not encourage innovation at a time when innovation is needed most, argue Adv. Ephraim Heiliczer and…